Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PARG inhibitor IDE161

An orally bioavailable, small molecule inhibitor of poly (ADP-Ribose) (PAR) glycohydrolase (PARG), with potential antineoplastic activity. Upon oral administration, PARG Inhibitor IDE161 targets, binds to and inhibits the activity of PARG, thereby inhibiting the hydrolysis of PAR chains by PARG. This attenuates DNA repair and induces mitotic arrest, ultimately leading to apoptosis. PARG, the only enzyme responsible for hydrolyzing PAR chains produced by poly (ADP-ribose) polymerase (PARP) 1, plays a key role in the resolution of PARP 1/2-dependent DNA damage repair.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	IDE 161 IDE-161 IDE161

PARG inhibitor IDE161

Search NCI's Drug Dictionary